{"id":"https://openalex.org/W7223199337","doi":"https://doi.org/10.64898/2026.10.13.26365459","title":"Characterizing the Emergence of Medetomidine in Southern California Fentanyl Markets","display_name":"Characterizing the Emergence of Medetomidine in Southern California Fentanyl Markets","publication_year":2026,"publication_date":"2026-10-22","ids":{"openalex":"https://openalex.org/W7223199337","doi":"https://doi.org/10.64898/2026.10.13.26365459"},"language":"en","primary_location":{"id":"doi:10.64898/2026.10.13.26365459","doi":"https://doi.org/10.64898/2026.10.13.26365459","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.10.13.26365459","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2026/10/22/2026.10.13.26365459.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},"volume":null,"type":"preprint","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.medrxiv.org/content/medrxiv/early/2026/10/22/2026.10.13.26365459.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5107419196","display_name":"Adam J Koncsol","orcid":"https://orcid.org/0000-0001-5984-2577","observed_orcids":["https://orcid.org/0000-0001-5984-2577"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Adam J. Koncsol","raw_affiliation_strings":["Dept. of Health Policy & Management, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, United States","Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States"],"raw_orcid":"https://orcid.org/0000-0001-5984-2577","affiliations":[{"raw_affiliation_string":"Dept. of Health Policy & Management, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, United States","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040264565","display_name":"Joseph R. Friedman","orcid":"https://orcid.org/0000-0002-5225-3267","observed_orcids":["https://orcid.org/0000-0002-5225-3267"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph R. Friedman","raw_affiliation_strings":["Department of Psychiatry, University of California, San Diego, San Diego, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, University of California, San Diego, San Diego, CA, United States","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052518236","display_name":"Caitlin A. Molina","orcid":"https://orcid.org/0009-0000-4795-116X","observed_orcids":["https://orcid.org/0009-0000-4795-116X"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Caitlin A. Molina","raw_affiliation_strings":["Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049122721","display_name":"Megan Grabill","orcid":"https://orcid.org/0000-0002-6699-2992","observed_orcids":["https://orcid.org/0000-0002-6699-2992"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Megan Grabill","raw_affiliation_strings":["Dept. of Anthropology, College of Social Sciences, University of California, Los Angeles, Los Angeles, CA, United States","Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Anthropology, College of Social Sciences, University of California, Los Angeles, Los Angeles, CA, United States","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047650633","display_name":"Morgan Godvin","orcid":"https://orcid.org/0009-0000-5688-3904","observed_orcids":["https://orcid.org/0009-0000-5688-3904"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Morgan E. Godvin","raw_affiliation_strings":["Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113478553","display_name":"Ruby Romero","orcid":"https://orcid.org/0000-0002-7977-2585","observed_orcids":["https://orcid.org/0000-0002-7977-2585"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruby Romero","raw_affiliation_strings":["Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053876009","display_name":"Elizabeth A. Samuels","orcid":"https://orcid.org/0000-0003-2414-110X","observed_orcids":["https://orcid.org/0000-0003-2414-110X"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth A. Samuels","raw_affiliation_strings":["Dept. of Emergency Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Emergency Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076986688","display_name":"Edward Sisco","orcid":"https://orcid.org/0000-0003-0252-1910","observed_orcids":["https://orcid.org/0000-0003-0252-1910"]},"institutions":[{"id":"https://openalex.org/I1321296531","display_name":"National Institute of Standards and Technology","ror":"https://ror.org/05xpvk416","country_code":"US","type":"government","lineage":["https://openalex.org/I1321296531","https://openalex.org/I1343035065"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward Sisco","raw_affiliation_strings":["National Institute of Standards and Technology, Gaithersburg, MD, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Institute of Standards and Technology, Gaithersburg, MD, United States","institution_ids":["https://openalex.org/I1321296531"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5038911498","display_name":"Chelsea L. Shover","orcid":"https://orcid.org/0000-0002-0728-4101","observed_orcids":["https://orcid.org/0000-0002-0728-4101"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chelsea L. Shover","raw_affiliation_strings":["Dept. of Health Policy & Management, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, United States","Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept. of Health Policy & Management, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, United States","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"Division of General Internal Medicine and Health Services Research, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States","institution_ids":["https://openalex.org/I161318765"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5107419196"],"corresponding_institution_ids":["https://openalex.org/I161318765"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10800","display_name":"Forensic Toxicology and Drug Analysis","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10800","display_name":"Forensic Toxicology and Drug Analysis","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.005400000140070915,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11860","display_name":"HIV, Drug Use, Sexual Risk","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/medetomidine","display_name":"medetomidine","score":0.9700000286102295},{"id":"https://openalex.org/keywords/fentanyl","display_name":"fentanyl","score":0.7979999780654907},{"id":"https://openalex.org/keywords/drug-adulteration","display_name":"drug adulteration","score":0.7429999709129333},{"id":"https://openalex.org/keywords/xylazine","display_name":"xylazine","score":0.734000027179718},{"id":"https://openalex.org/keywords/lidocaine","display_name":"lidocaine","score":0.7419999837875366},{"id":"https://openalex.org/keywords/enantiomer-determination","display_name":"enantiomer determination","score":0.6169999837875366},{"id":"https://openalex.org/keywords/drug-checking","display_name":"drug checking","score":0.6880000233650208},{"id":"https://openalex.org/keywords/dark-web","display_name":"dark web","score":0.5899999737739563},{"id":"https://openalex.org/keywords/southern-california","display_name":"Southern California","score":0.4970000088214874},{"id":"https://openalex.org/keywords/drug-overdose-risk","display_name":"drug overdose risk","score":0.5230000019073486}],"concepts":[{"id":"https://openalex.org/C2779520467","wikidata":"https://www.wikidata.org/wiki/Q427179","display_name":"Medetomidine","level":4,"score":0.9916999936103821},{"id":"https://openalex.org/C2781072394","wikidata":"https://www.wikidata.org/wiki/Q407541","display_name":"Fentanyl","level":2,"score":0.7702999711036682},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.4848000109195709},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4708000123500824},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4138999879360199},{"id":"https://openalex.org/C2780795376","wikidata":"https://www.wikidata.org/wiki/Q243547","display_name":"Ketamine","level":2,"score":0.41119998693466187},{"id":"https://openalex.org/C2779567708","wikidata":"https://www.wikidata.org/wiki/Q1658591","display_name":"Adulterant","level":2,"score":0.35679998993873596},{"id":"https://openalex.org/C2780820201","wikidata":"https://www.wikidata.org/wiki/Q173235","display_name":"Analgesic","level":2,"score":0.30079999566078186},{"id":"https://openalex.org/C2779591255","wikidata":"https://www.wikidata.org/wiki/Q426081","display_name":"Xylazine","level":3,"score":0.29319998621940613},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.273499995470047},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.2628999948501587},{"id":"https://openalex.org/C2780149897","wikidata":"https://www.wikidata.org/wiki/Q216935","display_name":"Lidocaine","level":2,"score":0.2533999979496002}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.64898/2026.10.13.26365459","doi":"https://doi.org/10.64898/2026.10.13.26365459","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.10.13.26365459","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2026/10/22/2026.10.13.26365459.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},{"id":"pmh:oai:pubmedcentral.nih.gov:13738906","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13738906/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"medRxiv","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.64898/2026.10.13.26365459","doi":"https://doi.org/10.64898/2026.10.13.26365459","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.10.13.26365459","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2026/10/22/2026.10.13.26365459.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1057431430","display_name":"LIMITING OVERDOSE THROUGH COLLABORATIVE ACTIONS IN LA COUNTY - LOS ANGELES COUNTY (LAC) IS CURRENTLY EXPERIENCING THE HIGHEST RATE OF OVERDOSE DEATHS IN OUR HISTORY DRIVEN BY FENTANYL AND METHAMPHETAMINE. WE PROPOSE A DATA-DRIVEN RESPONSE FOCUSED ON IMPROVING LINKAGE TO AND RETENTION IN CARE, EXPANDING OF HARM REDUCTION SERVICES TO THE PRIORITY POPULATIONS DESCRIBED BELOW, AND IMPROVING CLINICIAN AND HEALTH SYSTEMS PRACTICES THAT ALIGN WITH CDC GUIDELINES ON PRESCRIBING CONTROLLED SUBSTANCES AND ASAM, SAMHSA, AND OTHER APPLICABLE PRACTICE GUIDELINES ON LOW-THRESHOLD INITIATION OF CLINICALLY EFFECTIVE TREATMENT FOR OUD (SUCH AS MOUD) AND INITIATION OF TREATMENT CLINICALLY EFFECTIVE FOR STIMULANT USE DISORDER (STUD) INCLUDING CONTINGENCY MANAGEMENT AND OFF-LABEL MEDICATIONS FOR STUD. THE PROPOSED HARM REDUCTION SERVICES AND LINKAGE TO CLINICAL INTERVENTIONS FOR OUD AND STUD PRIORITIZES: (1) PEOPLE WHO USE OPIOIDS AND/OR SIMULANTS AND WHO ARE CURRENTLY NOT RECEIVING SPECIALTY SUD TREATMENT, (2) PEOPLE RECENTLY RELEASED FROM INCARCERATION, (3) PEOPLE EXPERIENCING HOMELESSNESS, AND (4) ANYONE WHO HAS EXPERIENCED A NON-FATAL OVERDOSE. THESE ARE THE PRIORITY POPULATIONS REFERENCED ELSEWHERE WITHIN THIS PROPOSAL. PROPOSED ACTIVITIES WILL DEPLOY INTERVENTIONS IN COMMUNITY, PUBLIC SAFETY, AND HEALTHCARE SETTINGS. FOR THE PRIORITY POPULATIONS DESCRIBED ABOVE, LA COUNTY PROPOSES TO REDUCE THE NUMBER OF OVERDOSE DEATHS IN LA COUNTY IN COMMUNITY, PUBLIC SAFETY, AND HEALTHCARE SETTINGS THROUGH: (1) EXPANDING PROGRAMMING THAT INCREASES THE INITIATION OF LOW THRESHOLD MEDICATIONS FOR OPIOID USE DISORDER (MOUD) AND THE FORTHCOMING AMERICAN SOCIETY OF ADDICTION MEDICINE AND IMPROVES ENGAGEMENT AND LINKAGE OF PRIORITY POPULATIONS WITHIN LA COUNTY TO CONTINUITY SUD TREATMENT AND MEDICAL, MENTAL HEALTH, AND SOCIAL SERVICES; (2) EXPANDING THE AVAILABILITY OF HARM REDUCTION SERVICES TO PRIORITY POPULATIONS IN EACH SETTING; (3) IMPROVING CLINICIAN AND HEALTH SYSTEMS ADHERENCE TO CDC GUIDELINES ON SAFER PRESCRIBING OF CONTROLLED SUBSTANCES AND ADOPTION OF BEST PRACTICES THAT INCLUDE THE LOW-THRESHOLD INITIATION OF MOUD IN ACCORDANCE WITH ESTABLISHED NATIONAL GUIDELINES, AND MANAGEMENT OF STUD IN ACCORDANCE WITH THE (FORTHCOMING) AMERICAN SOCIETY OF ADDICTION MEDICINE NATIONAL PRACTICE GUIDELINE INTERVENTIONS FOR STIMULANT USE DISORDER (ASAM STUD NPG), SPECIFICALLY INCLUDING NALOXONE PRESCRIPTION AND DISTRIBUTION AND REFERRAL TO COMMUNITY HARM REDUCTION SERVICES; (4) LAUNCHING A HARM REDUCTION FOCUSED ANTI-STIGMA MEDIA CAMPAIGN INVOLVING THE COMMUNITY, HEALTH CARE SYSTEMS, FIRST RESPONDERS, AND PWUD THAT LIFTS THE VOICES OF PWUD, INCREASES THE ACCEPTABILITY OF HARM REDUCTION POLICIES, SERVICES, AND PRACTICES, AND THAT REDUCES THE STIGMA FACING PWUD; (5) ENHANCED LAC DPH-SAPC\u2019S OVERDOSE SURVEILLANCE INFRASTRUCTURE TO PERFORM DATA ABSTRACTION TO INFORM TIMELY AND ACTIONABLE OVERDOSE RESPONSIVE INITIATIVES; (6) CONDUCTING TOXICOLOGY TESTING OF DRUG PRODUCT AND/OR PARAPHERNALIA AT LA COUNTY CONTRACTED AND CERTIFIED HARM REDUCTION SYRINGE SERVICES PROGRAMS AS DESCRIBED IN COMPONENT B. APPLYING FOR SURVEILLANCE COMPONENT B FUNDING. NOT APPLYING FOR COMPONENT C FUNDING","funder_award_id":"NH28CE003543","funder_id":"https://openalex.org/F4320332162","funder_display_name":"Centers for Disease Control and Prevention"},{"id":"https://openalex.org/G1447258349","display_name":null,"funder_award_id":"TL1TR001883","funder_id":"https://openalex.org/F4320337870","funder_display_name":"Clinical and Translational Science Institute, University of California, Los Angeles"},{"id":"https://openalex.org/G9000870517","display_name":"Predicting fatal and non-fatal overdose in Los Angeles County with Rapid Overdose Surveillance Dashboard to target street-based addiction treatment and harm reduction services","funder_award_id":"R01DA057630","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G9000899782","display_name":"J. NRSA Training Core","funder_award_id":"TL1TR001883","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"}],"funders":[{"id":"https://openalex.org/F4320311932","display_name":"James B. Pendleton Charitable Trust","ror":"https://ror.org/04tw4j633"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332162","display_name":"Centers for Disease Control and Prevention","ror":"https://ror.org/042twtr12"},{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"},{"id":"https://openalex.org/F4320337417","display_name":"National Center for Injury Prevention and Control","ror":"https://ror.org/0015x1k58"},{"id":"https://openalex.org/F4320337472","display_name":"National Center for Advancing Translational Sciences","ror":"https://ror.org/04pw6fb54"},{"id":"https://openalex.org/F4320337870","display_name":"Clinical and Translational Science Institute, University of California, Los Angeles","ror":"https://ror.org/04kpwcf85"},{"id":"https://openalex.org/F4320337899","display_name":"UCLA AIDS Institute","ror":null},{"id":"https://openalex.org/F4320337939","display_name":"Center for AIDS Research, University of California Los Angeles","ror":null}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223199337.pdf","grobid_xml":"https://content.openalex.org/works/W7223199337.grobid-xml"},"referenced_works_count":14,"referenced_works":["https://openalex.org/W2609701185","https://openalex.org/W4226064141","https://openalex.org/W4312566322","https://openalex.org/W4327601315","https://openalex.org/W4360965415","https://openalex.org/W4367041224","https://openalex.org/W4399459016","https://openalex.org/W4402221404","https://openalex.org/W4403414291","https://openalex.org/W4407186092","https://openalex.org/W4408724668","https://openalex.org/W4410000567","https://openalex.org/W4412568819","https://openalex.org/W4412823834"],"related_works":["https://openalex.org/W7213414903","https://openalex.org/W4410192469","https://openalex.org/W4416008848","https://openalex.org/W4413410681","https://openalex.org/W4412568819","https://openalex.org/W4410416465","https://openalex.org/W4414491103","https://openalex.org/W7163922495","https://openalex.org/W4416703164","https://openalex.org/W4409999452"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Medetomidine,":[2],"a":[3,34,80,201,235,242],"potent":[4,36],"sedative,":[5],"is":[6,239,252],"increasingly":[7],"present":[8],"in":[9,25,53,65,72,119,146,205,256,272,277,287,296],"fentanyl-related":[10],"hospitalizations":[11],"and":[12,44,127,177,182],"deaths.":[13],"Multiple":[14],"states":[15],"have":[16],"passed":[17],"legislation":[18],"to":[19,79,153,275],"control":[20],"xylazine\u2014a":[21],"pharmacologically":[22],"similar":[23],"sedative":[24],"the":[26,115,123,128,206,247,257,288,303],"illicit":[27],"opioid":[28],"supply.":[29,210,261],"Medetomidine":[30,47,199,251,293],"may":[31],"function":[32],"as":[33,180,196],"highly":[35],"substitute":[37],"for":[38,214],"xylazine":[39],"with":[40,113,140,173,267],"significant":[41,244],"overdose":[42],"risk":[43],"withdrawal":[45],"potential.":[46],"has":[48],"previously":[49],"been":[50],"described":[51],"mostly":[52],"eastern":[54],"U.S.":[55],"fentanyl":[56,120,141,176,209,260,266],"markets.":[57],"Here,":[58],"we":[59],"characterize":[60],"medetomidine-containing":[61],"drug":[62,77,82],"samples":[63,86,186,212,284,298],"obtained":[64,301],"Southern":[66,73,207,258],"California":[67,74,208,259],"2023\u20132026.":[68],"Methods":[69],"Anonymous":[70],"participants":[71],"voluntarily":[75],"provided":[76],"products":[78],"community-based":[81],"checking":[83],"program.":[84],"All":[85,184,211,321],"underwent":[87,105,188],"direct-analysis-in-real-time":[88],"mass":[89,99,166,315],"spectrometry":[90,100],"(DART-MS).":[91],"A":[92,102],"subset":[93,104],"was":[94,163,294,312,324],"quantified":[95],"by":[96,156],"liquid-chromatography":[97],"tandem":[98],"(LC-MS/MS).":[101],"smaller":[103],"enantiomeric":[106,189],"analysis.":[107],"We":[108],"calculated":[109],"other":[110],"compounds":[111],"co-present":[112,139],"medetomidine,":[114,126,219],"prevalence":[116,136],"of":[117,125,131,137,150,246,265,290,299,310],"medetomidine":[118,138,161,174,185,268,283,311,323],"over":[121],"time,":[122],"concentration":[124,162,309],"enantiomer":[129,215],"makeup":[130],"medetomidine.":[132],"Results":[133],"The":[134,159,168,263,307],"quarterly":[135],"rose":[142,269],"from":[143,225,270],"\u22486":[144],"%":[145,155,165,314],"May":[147,273],"2025":[148,274],"(month":[149],"first":[151],"detection)":[152],"\u224825":[154],"August":[157],"2026.":[158,279],"average":[160],"0.4":[164,313],"fraction.":[167],"most":[169],"common":[170],"co-detected":[171],"substances":[172],"were":[175,194,217,222,285],"adulterants":[178],"such":[179],"lidocaine":[181],"xylazine.":[183],"that":[187],"analysis":[190],"(n":[191],"=":[192],"13)":[193],"identified":[195],"racemic.":[197],"Conclusion":[198],"represents":[200],"rapidly":[202],"emerging":[203,254],"adulterant":[204,255],"assessed":[213],"status":[216],"racemic":[218],"suggesting":[220],"they":[221],"not":[223,326],"diverted":[224,327],"human":[226],"pharmaceutical":[227],"or":[228],"medical":[229],"supplies.":[230],"Given":[231],"its":[232],"high":[233],"potency,":[234],"small":[236],"amount":[237],"(<1.5%)":[238],"likely":[240],"still":[241],"physiologically":[243],"quantity":[245],"drug.":[248],"Highlights":[249],"-":[250,262,280,292,306,320],"an":[253],"share":[264],"6%":[271],"25%":[276],"Aug":[278],"Nearly":[281],"all":[282],"detected":[286],"presence":[289],"fentanyl.":[291],"found":[295],"two":[297],"DMT":[300],"via":[302],"dark":[304],"web.":[305],"mean":[308],"fraction":[316],"among":[317],"22":[318],"cases.":[319],"tested":[322],"racemic,":[325],"dexmedetomidine.":[328]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-10-23T00:00:00"}